- Non-Small Cell Lung Cancer (NSCLC) (single agent or in combination)
Dose:
Monotherapy (single-agent):
- Dose: 25–30 mg/m² IV once a week
- Administration: IV infusion over 6–10 minutes
Combination with Cisplatin:
- Dose: 25 mg/m² IV on days 1 and 8 of a 21-day cycle
- Administration: IV infusion over 6–10 minutes
- Metastatic Breast Cancer (after failure of prior therapies)
Dose:
Weekly dosing:
- Dose: 30 mg/m² IV once a week
- Administration: IV infusion over 6–10 minutes
Combination with other chemotherapy agents (e.g., in a 21-day cycle):
- Dose: 30 mg/m² IV on days 1 and 8 of a 3-week cycle
Administration: IV infusion over 6–10 minutes
- IM: 10 mg/mL in 1 mL, 5 mL, or 10 mL vials
- Oral capsules (where available): 20 mg, 30 mg
- Administered intravenously (IV) over 6–10 minutes
- Do not administered intrathecally (fatal neurotoxicity)
- Extravasation risk – ensure proper IV placement
- Class: Vinca alkaloid, chemotherapy agent
- Mechanism of Action:
Inhibits microtubule formation by binding to tubulin, preventing mitotic spindle formation, and causing cell cycle arrest in metaphase - Metabolism: Hepatic (via CYP3A4)
- Half-life: ~27–43 hours
- Excretion: Primarily through feces, minor renal excretion
- Neutropenia (dose-limiting)
- Nausea, vomiting, constipation
- Fatigue
- Peripheral neuropathy (mild)
- Mucositis
- Alopecia
- Hypersensitivity to vinorelbine or other vinca alkaloids
- Severe neutropenia or thrombocytopenia
- Severe hepatic impairment
- Pregnancy and breastfeeding
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): May ↑ vinorelbine levels → ↑ toxicity
- CYP3A4 inducers (e.g., rifampin, phenytoin): May ↓ effectiveness
- Other myelosuppressive agents: ↑ risk of bone marrow suppression
- Avoid with live vaccines due to risk of infection
Drug Status
| Availability | |
| Pregnancy | |
| Breastfeeding | |
| Schedule |
<
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Vinrel | 10mg | Injection | 1’s | PSM Pharma | PSM Pharma |